July 28, 2026 IQVIA Holdings Inc. Reports Strong Q2 2026 Financial Performance IQVIA Holdings Inc. achieved a revenue growth of $351 million in Q2 2026, marking an 8.7% increase year-over-year. The company's restructuring into two segments has positioned it well for future opportunities amidst rising costs and effective debt management.
July 28, 2026 IQVIA Holdings Inc. Reports Strong Second-Quarter 2026 Results IQVIA Holdings Inc. announced strong second-quarter 2026 results, featuring an 8.7% revenue increase and significant advancements in its Commercial and R&D Solutions segments. The company raised its 2026 full-year guidance, bolstered by record net new bookings and a robust backlog, indicating sustained growth potential.
July 16, 2026 IQVIA Advocates for Streamlined Clinical Development in Testimony Before Congress In a recent congressional hearing, IQVIA's Dr. Cynthia Verst proposed key recommendations to streamline early clinical development in the U.S. Her focus was on modernizing pathways for drug applications while ensuring patient safety and fostering collaboration between regulatory bodies and biopharmaceutical companies.
July 08, 2026 IQVIA Holdings Inc. to Announce Second-Quarter 2026 Results IQVIA Holdings Inc. will release its second-quarter 2026 financial results on July 28, 2026, followed by a conference call for stakeholders. The event aims to provide insights into the company's performance and future outlook, showcasing its role in the evolving healthcare landscape.
June 04, 2026 IQVIA Holdings Inc. Announces Pricing of Senior Notes IQVIA Holdings Inc. has priced €950 million in senior notes due 2033 to strengthen its financial position. The offering aims to refinance existing debt, providing stability and predictability in cash flow management.
June 03, 2026 IQVIA Holdings Inc. Announces Senior Notes Offering IQVIA Holdings Inc. has announced a €950 million senior notes offering to refinance existing debts and cover issuance costs. This move reflects the company's proactive financial strategy and commitment to enhancing its capital structure while adhering to regulatory compliance.
May 26, 2026 IQVIA Holdings Inc. Announces CEO's Participation at Jefferies Global Healthcare Conference IQVIA Holdings Inc. announces CEO Ari Bousbib's participation in the Jefferies Global Healthcare Conference on June 3, 2026. The event will cover the company's strategies and commitment to enhancing healthcare through innovative technologies and AI.
May 07, 2026 IQVIA Board of Directors Approves $2 Billion Increase in Share Repurchase Authorization IQVIA Holdings Inc. has approved a $2 billion increase in its share repurchase program, raising total authorization to $3.2 billion. This move reflects the company's confidence in its financial strength and commitment to maximizing shareholder returns through strategic capital management.
May 06, 2026 IQVIA Holdings Inc. Announces Key Presentation at Bank of America Health Care Conference IQVIA Holdings Inc. announces CFO Mike Fedock will present at the Bank of America Health Care Conference on May 13, 2026. The event will highlight industry trends and innovations, with a live webcast available for broader access.
May 05, 2026 IQVIA Reports Strong First-Quarter Results for 2026 IQVIA Holdings Inc. reported strong first-quarter results for 2026, with total revenues reaching $4.15 billion, driven by growth in Commercial and R&D Solutions. The company's outlook remains positive, bolstered by a significant backlog and effective cash management strategies.
May 05, 2026 IQVIA Holdings Inc. Reports Strong Q1 2026 Results: Revenue Growth and Strategic Restructuring IQVIA Holdings Inc. reported robust Q1 2026 results with $4.15 billion in revenue, an 8.4% increase year-over-year. The company restructured its segments to enhance operational efficiency while maintaining a focus on patient solutions and international growth.
April 15, 2026 IQVIA Holdings Inc. to Release First-Quarter 2026 Financial Results IQVIA Holdings Inc. is set to release its Q1 2026 financial results on May 5. The announcement will be followed by a conference call for stakeholders to discuss insights and strategies. A replay will be available post-event for those unable to attend live.
March 16, 2026 IQVIA Launches Groundbreaking IQVIA.ai Platform Powered by NVIDIA IQVIA has launched IQVIA.ai, a groundbreaking AI platform designed to optimize operations in the life sciences sector. Powered by NVIDIA technology, it integrates intelligent solutions into workflows, enhancing efficiency while maintaining compliance. The platform promises to accelerate research and improve patient outcomes.
March 02, 2026 IQVIA Holdings Inc. to Present at Barclays 28th Annual Global Healthcare Conference IQVIA Holdings Inc. will present at the Barclays 28th Annual Global Healthcare Conference on March 12, 2026, led by CFO Mike Fedock. The event will be available via live audio webcast, offering insights into IQVIA's innovations and commitment to healthcare improvement.
March 02, 2026 IQVIA Holdings Inc. Announces CEO's Upcoming Speech at Leerink Partners Global Healthcare Conference IQVIA Holdings Inc. announces CEO Ari Bousbib's speech at the 2026 Global Healthcare Conference, set for March 9. The event will feature key insights into the company's strategies and healthcare trends, available via live webcast.
February 27, 2026 IQVIA Releases 2025 Sustainability Report: A Commitment to People, Public Health, and Planet IQVIA's 2025 Sustainability Report highlights its commitment to global health through employee development, AI advancements, and enhanced healthcare access. The company also emphasizes environmental sustainability and has received multiple accolades for its efforts.
February 25, 2026 IQVIA Expands Drug Discovery Capabilities with Acquisition of Assets from Charles River Laboratories IQVIA has announced the acquisition of drug discovery assets from Charles River Laboratories, enhancing its capabilities in the life sciences sector. This strategic move allows IQVIA to accelerate drug discovery processes while meeting the rising demand for non-animal research methods. The integration of these assets will create a comprehensive end-to-end drug discovery platform, benefiting pharmaceutical and biotech sponsors.
February 18, 2026 IQVIA to Present at Citi's 2026 Unplugged MedTech and Life Sciences Access Day IQVIA Holdings Inc. will present at Citi's 2026 Unplugged MedTech and Life Sciences Access Day, featuring key executives discussing future strategies. The event emphasizes transparency and investor engagement, with a live webcast available for stakeholders.
February 17, 2026 IQVIA Holdings Inc. Reports Resilient Financial Performance in 2025 IQVIA Holdings Inc. reported revenues of $16.31 billion in 2025, reflecting a 5.9% increase. The company demonstrated resilience through strategic acquisitions and a focus on innovative solutions, positioning itself for future growth in the healthcare sector.
February 10, 2026 IQVIA and Duke Clinical Research Institute Forge Strategic Partnership to Tackle Obesity IQVIA and the Duke Clinical Research Institute have formed a strategic partnership to enhance clinical research in obesity. This collaboration aims to streamline trial processes and improve patient outcomes by leveraging each organization's strengths in research and data analytics.
February 05, 2026 IQVIA Holdings Inc. Reports Strong Fourth-Quarter and Full-Year 2025 Results IQVIA Holdings Inc. reported strong financial results for Q4 and full-year 2025, showcasing substantial revenue growth across key segments despite industry challenges. With a robust backlog and strategic focus, the company is well-positioned for continued success in 2026.
January 29, 2026 IQVIA and Boehringer Ingelheim Forge Strategic Collaboration to Transform Global Commercial Data IQVIA and Boehringer Ingelheim have partnered to enhance data management in life sciences through IQVIA's DaaS+ technology. This collaboration aims to unify Boehringer's global commercial datasets, improving operational efficiencies and fostering data-driven decision-making.
January 22, 2026 IQVIA Secures Top Spot in Fortune’s Most Admired Companies List for Fifth Consecutive Year IQVIA Holdings Inc. has been recognized as the top company in the Health Care sector on Fortune's Most Admired Companies List for the fifth consecutive year. This accolade highlights IQVIA's consistent performance across key corporate attributes, reflecting its commitment to innovation and improving global health outcomes.
January 20, 2026 IQVIA Holdings Inc. Set to Release Q4 and Full-Year 2025 Results IQVIA Holdings Inc. will release its Q4 and full-year 2025 financial results on February 5, 2026. A conference call will allow stakeholders to engage with executives and gain insights into the company's performance and strategic direction.
December 02, 2025 IQVIA Partners with AWS to Transform Healthcare with AI IQVIA has partnered with AWS to enhance healthcare through AI, focusing on clinical trial automation and data-driven insights. This collaboration aims to accelerate drug development and improve patient outcomes, marking a significant step in the digital transformation of life sciences.
November 05, 2025 Dr. William G. Kaelin Jr. Joins IQVIA's Board of Directors IQVIA has appointed Dr. William G. Kaelin Jr. to its Board of Directors, bringing invaluable expertise in oncology and biomedical innovation. His distinguished career and accolades, including a Nobel Prize, position him to significantly influence the company's mission of improving patient outcomes.
October 28, 2025 IQVIA Reports Strong Third-Quarter 2025 Results IQVIA Holdings Inc. announced impressive Q3 2025 results, achieving $4.1 billion in revenue, driven by growth across its business segments. With a strong backlog and positive market demand, the company is well-positioned for continued success in the healthcare sector.
October 28, 2025 IQVIA Holdings Inc. Reports Strong Q3 2025 Results IQVIA Holdings Inc. announced a strong performance for Q3 2025 with revenues of $4.1 billion, reflecting a 5.2% year-over-year increase. The company's strategic initiatives and efficient operations contributed significantly to its growth across all business segments.
October 21, 2025 IQVIA Holdings Inc. CEO to Present at UBS Global Healthcare Conference IQVIA's CEO Ari Bousbib will present at the UBS Global Healthcare Conference on November 11, 2025, discussing the company's strategic direction. The presentation will be available via live audio webcast and aims to provide valuable insights into IQVIA's role in healthcare innovation and patient safety.
September 30, 2025 IQVIA Holdings Inc. Set to Announce Third-Quarter 2025 Results IQVIA Holdings Inc. is set to release its Q3 2025 financial results on October 28, 2025. The earnings conference call will provide stakeholders insights into the company's performance and future strategies. Investors can access the release and participate in the call through registration.
July 22, 2025 IQVIA Holdings Inc. Reports Solid Growth in Q2 2025 IQVIA Holdings Inc. demonstrated strong revenue growth of 5.3% in Q2 2025, totaling $4.01 billion. The company’s strategic focus on operational efficiency and its Connected Intelligence platform are key drivers of this performance, although it faces challenges from rising costs.
May 07, 2025 IQVIA Holdings Inc. Announces CFO Ron Bruehlman to Speak at Bank of America Annual Health Care Conference IQVIA Holdings Inc. has announced that CFO Ron Bruehlman will speak at the Bank of America Annual Health Care Conference on May 13, 2025. The event will focus on the company's strategic direction and responsible AI use in healthcare, with a live audio webcast available for those interested.
May 06, 2025 IQVIA Holdings Inc.: A Strong Start to 2025 IQVIA Holdings Inc. reported a solid start to 2025 with Q1 revenues of $3.82 billion, driven by strong performance in Technology & Analytics Solutions. Despite challenges in some segments, the company showcases resilience and strategic growth, positioning itself well for future opportunities in healthcare.
May 06, 2025 IQVIA Reports Strong First-Quarter 2025 Results Amidst Market Uncertainty IQVIA Holdings Inc. reported solid first-quarter 2025 results, with a 2.5% revenue increase and strong performance in Technology & Analytics Solutions. The company raised its full-year guidance, highlighting resilience amidst market challenges.
April 28, 2025 IQVIA Celebrates Excellence in Healthcare Leadership: Marie E. Lamont and Dr. Joanne Hackett Earn Prestigious HBA Awards IQVIA celebrates the achievements of Marie E. Lamont and Dr. Joanne Hackett, honored by the HBA for their significant contributions to healthcare. Lamont's leadership in patient advocacy and Hackett's pioneering work in precision medicine highlight their commitment to advancing women in healthcare.
April 23, 2025 IQVIA Honored as a Leader in Generative AI by Everest Group IQVIA has been honored as a leader in generative AI by the Everest Group, being the only clinical research organization to receive this top ranking. The recognition emphasizes IQVIA's innovative approach to integrating AI in healthcare, enhancing clinical trials and patient outcomes while maintaining ethical governance.
April 21, 2025 IQVIA Holdings Inc. to Announce First-Quarter 2025 Results IQVIA Holdings Inc. will announce its first-quarter 2025 financial results on May 6, 2025. A conference call will follow at 9:00 AM ET for stakeholders to gain insights into the company's performance and future strategies.
April 15, 2025 IQVIA Holdings Inc. Reports Stabilization and Improvement in Biopharma R&D Metrics IQVIA's latest report reveals significant advancements in biopharma R&D for 2024, including a ten-year high in funding and the stabilization of clinical trials. The industry is adapting to challenges while enhancing productivity and innovation.
March 10, 2025 IQVIA Holdings Inc. Emerges as a Leader in Decentralized Clinical Trials IQVIA Holdings Inc. has been recognized as a leader in decentralized clinical trials by IDC MarketScape, reflecting its commitment to innovative technologies and patient-centric solutions. The report highlights the importance of DCTs in modern clinical research, particularly post-COVID-19, and IQVIA's robust strategies and expertise position it well for future advancements in the field.
March 04, 2025 IQVIA Laboratories Launches Site Lab Navigator: A Game Changer for Clinical Trials IQVIA Laboratories has launched Site Lab Navigator, an innovative e-Requisition solution designed to streamline lab workflows in clinical trials. This platform automates requisitions, enhances compliance, and significantly reduces administrative burdens, leading to improved quality and execution of studies.
February 24, 2025 IQVIA AI Assistant Wins 2024 PM360 Innovation Award IQVIA's AI Assistant has won the 2024 PM360 Innovation Award for its transformative impact on healthcare insights. Launched in September 2024, it utilizes advanced data science to deliver rapid and precise responses, enhancing decision-making across the industry while ensuring compliance with healthcare standards.
February 21, 2025 Iqvia Holdings Inc.: Insights Ahead of TD Cowen Annual Health Care Conference Iqvia Holdings Inc. CFO Ron Bruehlman will present at the TD Cowen Annual Health Care Conference on March 4, 2025. The event will focus on the latest developments in healthcare intelligence and Iqvia's commitment to responsible AI use and patient privacy.
February 20, 2025 IQVIA Holdings Inc. Unveils 2024 Sustainability Report: A Commitment to a Healthier Future IQVIA's 2024 Sustainability Report reveals significant advancements in sustainability, including a focus on employee development, enhancing healthcare access, and reducing emissions by 27%. The report highlights the company's innovative use of AI and its commitment to addressing global health challenges.
February 18, 2025 SWOT Analysis of IQVIA Holdings Inc. in 2025 This SWOT analysis reviews IQVIA Holdings Inc. in 2025, detailing its strengths like extensive data resources and technological innovation, alongside challenges such as contractual risks and intense competition. Opportunities for market expansion and strategic acquisitions are also discussed, providing insight into its future in the life sciences industry.
February 13, 2025 IQVIA Holdings Inc. Reports Strong Financial Performance in 2024 IQVIA Holdings Inc. announced its 2024 financial results, highlighting an 11% increase in operating income and significant cash flow growth. The company continues to expand its Technology & Analytics Solutions while strategically navigating market challenges.
February 06, 2025 IQVIA Holdings Inc. Reports Strong Financial Results for Q4 and Full-Year 2024 IQVIA Holdings Inc. reported impressive Q4 and full-year 2024 financial results, highlighting revenue growth across key segments. The company reaffirmed its positive outlook for 2025 amid a challenging market.
October 31, 2024 IQVIA Holdings Inc. Reports Robust Q3 Financial Results for 2024 IQVIA Holdings Inc. reported strong Q3 2024 financial results with revenues of $3.89 billion, driven by its Technology & Analytics Solutions segment. Despite a decline in net income, the company remains focused on innovation and market adaptation, positioning itself as a key player in healthcare.
July 22, 2024 IQVIA Holdings Inc. Reports Strong Q2 2024 Earnings Amidst Market Dynamics IQVIA Holdings Inc. reported a 22% increase in net income for Q2 2024, reaching $363 million. Despite growth in technology and research segments, challenges arose in contract sales. The company continues to enhance its market position through strategic partnerships and innovative solutions.
May 02, 2024 IQVIA Holdings Inc. Reports Q1 2024 Earnings: Steady Growth Amidst Rising Costs IQVIA Holdings Inc. reported a 2.3% revenue growth in Q1 2024, reaching $4,637 million. While facing rising operational costs, the company remains financially robust with strong performance in its Research & Development Solutions segment. Future growth strategies focus on enhancing technological capabilities.
